Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group" or the "Company") have announced the results of the Phase II, randomised, double blind, placebo controlled, dose-ranging trial of Cogane™ in unmedicated patients with early-stage Parkinson's disease ("CONFIDENT-PD"). Analysis...